论文部分内容阅读
目的观察比较奥沙利铂联合替吉奥与PF(顺铂+5-氟尿嘧啶)方案应用于晚期胃癌患者一线治疗中的效果。方法选取医院收治的晚期胃癌患者60例,根据治疗方案的不同分为观察组和对照组,每组30例。观察组采用奥沙利铂与替吉奥联合治疗,对照组采用PF方案治疗,观察2组近期、远期临床疗效与安全性。结果在近期疗效中,观察组总有效率为76.7%,高于对照组的50.0%(P<0.05)。2组远期疗效相当,但观察组的中位存活时间为10个月,对照组则为9个月。观察组不良反应发生率为36.7%,低于对照组的63.3%(P<0.05)。结论奥沙利铂联合替吉奥方案应用于晚期胃癌患者的一线治疗,给药方便,不良反应少,具有较高的临床应用价值。
Objective To observe and compare the efficacy of oxaliplatin combined with tigiao and PF (cisplatin + 5-fluorouracil) in the first-line treatment of patients with advanced gastric cancer. Methods Sixty patients with advanced gastric cancer admitted to our hospital were selected and divided into observation group and control group according to different treatment regimens, 30 cases in each group. The observation group was treated with oxaliplatin combined with tioguanide and the control group with PF regimen. The clinical efficacy and safety of the two groups were observed. Results In the short term, the total effective rate in the observation group was 76.7%, which was higher than that in the control group (50.0%, P <0.05). The long-term efficacy was comparable in both groups, but the median survival time in the observation group was 10 months compared with 9 months in the control group. The incidence of adverse reactions in the observation group was 36.7%, lower than 63.3% in the control group (P <0.05). Conclusion The combination of oxaliplatin and tioguanide in the first-line treatment of patients with advanced gastric cancer has the advantages of convenient administration, less adverse reactions and high clinical value.